Physician profile
Alfonso L Sabater
NPI 1760841704
$39,947.07
in general payments reported to CMS, 2019-2025
23 companies · $7,968 in 2025
The $7,968 reported for 2025 was more than what 93% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $83.29 · 2021: $2,841 · 2022: $25K · 2023: $1,217 · 2024: $2,106 · 2025: $7,968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,474 · Food and Beverage: $2,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,473.50 |
| Food and Beverage | $2,817.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $25,459.92 | 2021-2025 | |
| Recordati_rare_diseases_inc. | $4,165.00 | 2022 | |
| Bausch & Lomb Americas INC. | $2,549.39 | 2023-2025 | Stellaris, Miebo, Ic-8 Apthera Iol |
| Astrazeneca Pharmaceuticals Lp | $1,611.00 | 2025 | |
| Krystal Biotech INC | $1,100.00 | 2025 | |
| Abbvie INC. | $1,019.76 | 2022-2023 | Durysta |
| Dompe US, INC. | $589.74 | 2021-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $580.49 | 2022-2025 | Acthar |
| Quidel Corporation | $415.52 | 2019-2022 | |
| Harrow Eye, LLC | $318.47 | 2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $282.41 | 2019-2024 | Cequa |
| Biotissue Holdings INC. | $272.24 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $236.11 | 2021-2022 | |
| Glaukos Corporation | $217.59 | 2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $204.10 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $161.89 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $156.19 | 2022-2023 | Tyrvaya |
| Alcon Vision LLC | $152.86 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $130.16 | 2019-2021 | |
| Ortho-Clinical Diagnostics, INC. | $123.42 | 2025 | Inflammadry |
| Allergan, INC. | $122.50 | 2021 | |
| Thea Pharma INC. | $57.39 | 2022 | |
| Santen INC. | $20.92 | 2023 | Verkazia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfonso Sabater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.